Silvana Martino

Summary

Affiliation: Cancer Institute Medical Group
Country: USA

Publications

  1. ncbi request reprint Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene
    Silvana Martino
    Cancer Institute Medical Group, 2001 Santa Monica Blvd, Ste 560W, Santa Monica, CA 90404, USA
    J Natl Cancer Inst 96:1751-61. 2004
  2. ncbi request reprint Safety assessment of raloxifene over eight years in a clinical trial setting
    Silvana Martino
    The Angeles Clinic and Research Institute, Santa Monica, CA 90404, USA
    Curr Med Res Opin 21:1441-52. 2005
  3. ncbi request reprint The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials
    Silvana Martino
    The John Wayne Cancer Institute, St Johns Health Center, Santa Monica, California, USA
    Oncologist 9:116-25. 2004
  4. doi request reprint Prognostic value of basal phenotype in HER2-overexpressing breast cancer
    Sanjay P Bagaria
    Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA
    Ann Surg Oncol 19:935-40. 2012
  5. doi request reprint Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women
    Olga M Olevsky
    Angeles Clinic and Research Institute, Santa Monica, CA 90404, USA
    Menopause 15:790-6. 2008
  6. ncbi request reprint Prediction of breast tumor progression by integrity of free circulating DNA in serum
    Naoyuki Umetani
    Department of Molecular Oncology and the Joyce Eisenberg Breast Center, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    J Clin Oncol 24:4270-6. 2006
  7. ncbi request reprint A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
  8. ncbi request reprint Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk
    Marc E Lippman
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 12:5242-7. 2006
  9. ncbi request reprint Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17
    Edith A Perez
    St Michael s Hospital, Toronto, Canada
    J Clin Oncol 24:3629-35. 2006
  10. ncbi request reprint Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:295-300. 2006

Collaborators

Detail Information

Publications41

  1. ncbi request reprint Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene
    Silvana Martino
    Cancer Institute Medical Group, 2001 Santa Monica Blvd, Ste 560W, Santa Monica, CA 90404, USA
    J Natl Cancer Inst 96:1751-61. 2004
    ..We conducted the Continuing Outcomes Relevant to Evista (CORE) trial to examine the effect of 4 additional years of raloxifene therapy on the incidence of invasive breast cancer in women in MORE who agreed to continue in CORE...
  2. ncbi request reprint Safety assessment of raloxifene over eight years in a clinical trial setting
    Silvana Martino
    The Angeles Clinic and Research Institute, Santa Monica, CA 90404, USA
    Curr Med Res Opin 21:1441-52. 2005
    ..The aim of this study was to assess the safety of raloxifene over 8 years in 4011 postmenopausal women with osteoporosis in a clinical trial setting through adverse event reporting...
  3. ncbi request reprint The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials
    Silvana Martino
    The John Wayne Cancer Institute, St Johns Health Center, Santa Monica, California, USA
    Oncologist 9:116-25. 2004
    ..Completion of these trials will provide important information about the occurrence of invasive breast cancer in postmenopausal women and the efficacy of raloxifene for breast cancer risk reduction...
  4. doi request reprint Prognostic value of basal phenotype in HER2-overexpressing breast cancer
    Sanjay P Bagaria
    Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA
    Ann Surg Oncol 19:935-40. 2012
    ..We investigated the clinical relevance of this basal-HER2+ subtype within HER2-overexpressing breast tumors...
  5. doi request reprint Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women
    Olga M Olevsky
    Angeles Clinic and Research Institute, Santa Monica, CA 90404, USA
    Menopause 15:790-6. 2008
    ..It has a more favorable toxicity profile than tamoxifen and provides an alternative for postmenopausal women...
  6. ncbi request reprint Prediction of breast tumor progression by integrity of free circulating DNA in serum
    Naoyuki Umetani
    Department of Molecular Oncology and the Joyce Eisenberg Breast Center, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    J Clin Oncol 24:4270-6. 2006
    ..Serum DNA integrity, the ratio of longer fragments to total DNA, may be clinically useful for detecting breast cancer progression...
  7. ncbi request reprint A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
    ..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy...
  8. ncbi request reprint Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk
    Marc E Lippman
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 12:5242-7. 2006
    ..To assess the effect of raloxifene, indicated for osteoporosis treatment and prevention, on invasive breast cancer in subgroups of postmenopausal women defined by risk factors for breast cancer...
  9. ncbi request reprint Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17
    Edith A Perez
    St Michael s Hospital, Toronto, Canada
    J Clin Oncol 24:3629-35. 2006
    ..17B evaluated bone turnover markers and bone mineral density (BMD) in postmenopausal women randomly assigned to MA.17, a placebo-controlled trial of letrozole after standard adjuvant tamoxifen...
  10. ncbi request reprint Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:295-300. 2006
    ..Analyses were conducted to examine the relationships between duration of treatment on MA.17 and outcomes...
  11. ncbi request reprint Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women
    Timothy J Whelan
    McMaster University, Hamilton, Canada
    J Clin Oncol 23:6931-40. 2005
    ..To evaluate the impact of letrozole compared with placebo after adjuvant tamoxifen on quality of life (QOL) in the MA.17 trial...
  12. ncbi request reprint Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)
    Nancy E Davidson
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 409, Baltimore, MD 21231, USA
    J Clin Oncol 23:5973-82. 2005
    ..Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast cancer. The value of combined therapy has not been clearly established...
  13. doi request reprint Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17
    Hyman B Muss
    University of Vermont College of Medicine, 1 South Prospect St, Saint Joseph 3400, Burlington, VT 05401, USA
    J Clin Oncol 26:1956-64. 2008
    ..Breast cancer incidence increases with age and more than 1,300 women age 70 years or older were enrolled onto MA.17, making it ideal to explore the benefits, toxicities, and quality of life (QOL) impact of letrozole on older women...
  14. doi request reprint Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen
    Paul E Goss
    Massachusetts General Hospital Cancer Center, 55 Fruit St, Lawrence House, LRH 302, Boston, MA 02114, USA
    J Clin Oncol 26:1948-55. 2008
    ..When the trial was unblinded, patients who received placebo (PLAC) were offered LET...
  15. doi request reprint Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory
    Sunil S Badve
    Eastern Cooperative Oncology Group, Boston, MA, USA
    J Clin Oncol 26:2473-81. 2008
    ....
  16. pmc Weekly paclitaxel in the adjuvant treatment of breast cancer
    Joseph A Sparano
    Eastern Cooperative Oncology Group, Philadelphia, USA
    N Engl J Med 358:1663-71. 2008
    ..We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer...
  17. doi request reprint Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626
    J Wendall Goodwin
    Cancer Research for the Ozarks, 1730 E Republic Rd, Suite V, Springfield, MO 65804, USA
    J Clin Oncol 26:1650-6. 2008
    ..Prior progestin studies treating hot flashes in women have been short duration and single dose. This study tests the progestin megestrol acetate (MA) at two doses versus placebo over 6 months...
  18. ncbi request reprint Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623
    Halle C F Moore
    Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 25:1677-82. 2007
    ....
  19. ncbi request reprint Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
    Paul E Goss
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:2006-11. 2007
    ..MA.17 randomized postmenopausal women after 5 years of tamoxifen, to letrozole or placebo. We present outcomes according to tumor receptor status...
  20. ncbi request reprint Impact of a peer-delivered telephone intervention for women experiencing a breast cancer recurrence
    Carolyn Cook Gotay
    Cancer Research Center of Hawaii, Honolulu, HI 96822, USA
    J Clin Oncol 25:2093-9. 2007
    ..The Southwest Oncology Group conducted a phase III randomized trial to evaluate the effectiveness of a brief telephone intervention...
  21. ncbi request reprint HER2 and response to paclitaxel in node-positive breast cancer
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 357:1496-506. 2007
    ..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both...
  22. pmc Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
    Lori J Goldstein
    Eastern Cooperative Oncology Group, Boston, MA, USA
    J Clin Oncol 26:4063-71. 2008
    ..Genomic classifiers offer the potential to more accurately identify individuals who benefit from chemotherapy than clinicopathologic features...
  23. pmc Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197
    Lori J Goldstein
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:4092-9. 2008
    ..The purpose of this trial was to determine whether adjuvant AT improved disease-free survival compared with AC in operable breast cancer...
  24. doi request reprint Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 26:1231-8. 2008
    ..To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial...
  25. doi request reprint Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897
    Patricia A Ganz
    School of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 650 Charles Young Dr South, Room A2 125 CHS, Los Angeles, CA 90095 6900, USA
    J Clin Oncol 26:1223-30. 2008
    ..The late cardiac effects of adjuvant anthracycline therapy in survivors of early-stage breast cancer have had limited study. Subclinical and clinical cardiac late effects may contribute to added comorbidity over time...
  26. ncbi request reprint Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)
    Hannah M Linden
    Puget Sound Oncology Consortium, Southwest Oncology Group Statistical Center, Seattle, WA, USA
    J Clin Oncol 25:656-61. 2007
    ....
  27. ncbi request reprint HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial
    Edith A Perez
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 24:3032-8. 2006
    ..To evaluate concordance between local and central laboratory HER2 testing results in patients from the North Central Cancer Treatment Group (NCCTG) N9831 adjuvant trial of trastuzumab...
  28. ncbi request reprint Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of
    Saul E Rivkin
    Swedish Cancer Institute, Seattle, Washington, USA
    Cancer 97:21-9. 2003
    ....
  29. ncbi request reprint Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)
    George W Sledge
    Cancer Pavillion, Indiana University Medical Center, 535 Barnhill Drive, Room RT473, Indianapolis, IN 46202 5112, USA
    J Clin Oncol 21:588-92. 2003
    ..Patients receiving single-agent doxorubicin or paclitaxel were crossed over to the other agent at time of progression...
  30. ncbi request reprint Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatment
    Nancy Ellerbroek
    Providence Holy Cross Cancer Center, Los Angeles, California, USA
    Breast J 9:74-8. 2003
    ..Additional study is needed to determine optimal timing, long-term toxicity, and potential benefits of concurrent radiation therapy and paclitaxel...
  31. ncbi request reprint Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    I Craig Henderson
    University of California at San Francisco, San, Francisco, CA 94143, USA
    J Clin Oncol 21:976-83. 2003
    ..This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival...
  32. ncbi request reprint Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia
    Marc L Citron
    ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042, USA
    J Clin Oncol 21:1431-9. 2003
    ....
  33. ncbi request reprint A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester School of Medicine, Strong Memorial Hospital, Rochester, NY 14642 0001, USA
    Breast Cancer Res Treat 85:143-50. 2004
    ..To evaluate whether the high complete response (CR) rates for the combination of doxorubicin and paclitaxel in metastatic breast cancer observed in two European studies could be replicated in a multi-institutional cooperative group trial...
  34. ncbi request reprint Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study
    Lorie L Hughes
    Department of Radiation Oncology, WellStar Kennestone Hospital, Marietta, GA 30060, USA
    Cancer 101:969-72. 2004
    ..In the current study, we report the efficacy of pelvic RT with this dose-fractionation scheme in the induction of ovarian ablation...
  35. ncbi request reprint HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study
    Grazia Arpino
    Breast Center, Baylor College of Medicine, Methodist Hospital, Houston, Texas, USA
    Clin Cancer Res 10:5670-6. 2004
    ..Evidence of resistance from clinical studies has been inconsistent. The present study examined whether HER-2 gene amplification or HER-1 expression predicted response to tamoxifen...
  36. ncbi request reprint Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
    Edith A Perez
    North Central Cancer Treatment Group, Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 22:3700-4. 2004
    ....
  37. ncbi request reprint Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
    Paul E Goss
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Natl Cancer Inst 97:1262-71. 2005
    ..This report presents updated findings from the trial...
  38. ncbi request reprint Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  39. ncbi request reprint Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-010
    Laura F Hutchins
    University of Arkansas for Medical Sciences, Little Rock, AR, USA
    J Clin Oncol 23:8313-21. 2005
    ....
  40. pmc Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    JAMA 295:1658-67. 2006
    ..Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy...
  41. ncbi request reprint Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
    Patrick C Roche
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    J Natl Cancer Inst 94:855-7. 2002
    ..The concordance for central HercepTest and central FISH assays was 92%. The poor concordance (74%) between local and central testing for HER2 status has led to modifications in the eligibility criteria for N9831...